Work

Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate

Year: 2016

Type: conference-abstract

DOI: 10.1183/13993003.congress-2016.pa1555

Authors: Timothy Aksamit, Tiemo-Joerg Bandel, Margarita Criollo, Anthony De Soyza, Stuart Elborn, Elaine Montegriffo, Elisabeth Operschall, Eva Polverino, Kevin Winthrop, Robert Wilson

Institutions: Mayo Clinic, Bayer (Germany), Freeman Hospital, Belfast City Hospital, Bayer (United Kingdom), Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Oregon Health & Science University, Royal Brompton Hospital

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2554833065

Cites:

Cited by:

Related to: 10